Autres langues Ipsen

Actions

IPN

FR0010259150

Produits pharmaceutiques

PEA

Marché Fermé - Euronext Paris 17:55:00 12/10/2026			Varia. 5j.	Varia. 1 janv.
144,10 ^EUR	+0,98 %		+2,49 %	+21,09 %

08/10	Jefferies prudent sur Ipsen
08/10	Tesco encaisse, OPmobility décaisse

Autres langues

28/09	IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026
25/09	US FDA approves Mirum's drug for rare bone disorder
22/09	IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2026
22/09	European Pharma Leaders Push for National Reforms to Boost Investment
22/09	Europe Is Losing the Pharma Investment Race — But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi
22/09	European drugmakers call for faster trials, more spending to compete with US, China
21/09	Europe's STOXX 600 rallies on tech, banks strength as oil prices retreat
21/09	Ipsen Shares Fall After Early Launch of U.S. Generic Rival
21/09	Europe's STOXX 600 rises on tech rally, easing oil prices
21/09	El europeo STOXX 600 sube ante el repunte del sector tecnológico y el retroceso del petróleo
21/09	Europe's STOXX 600 gains as tech rallies, oil retreat eases nerves
18/09	Ipsen Announces Board and Committee Changes
18/09	Ipsen appoints Mariette Finet to its Board of Directors
18/09	AlphaValue/Baader Europe Ups Price Target, Forecasts for Ipsen on 'Solid' H1 Performance
17/09	Ipsen : Incorporating solid H1 operational performance + guidance upgrade
15/09	IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026
14/09	IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026
11/09	Health Care Flat as Traders Rotate Back Into Fuel-Sensitive Sectors - Health Care Roundup
07/09	IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026
31/08	IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2026
24/08	IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2026
21/08	Ipsen S.A. completed the acquisition of Kartos Therapeutics, Inc.
21/08	Ipsen Wraps Up Purchase of US-based Kartos Therapeutics
21/08	Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
20/08	Cancer vaccines finally garner the spotlight